Jul 27, 2026
•
9 min read
Lilly's triple hormone drug delivered again. Plus tariffs hit Friday and Otsuka landed an ADHD approval.
Jul 24, 2026
Its first lung cancer drug, weeks after closing. Plus a transatlantic breast cancer split.
Jul 23, 2026
7 min read
Indian pharma stocks fell hard. Plus pharma lobbies to soften the China restrictions.
Jul 22, 2026
The obesity giants are in federal court now. Plus Novartis opens earnings with 3% growth.
No one deals like Lilly. Plus the readouts that define the week ahead.
Novartis got full approval, Vera's in, Vertex is next. Plus a soft start to earnings season.
Merck cracked the first oral PCSK9. And we map how the China fight actually ends.
An unprecedented tau drop, a missed endpoint, an 8% slide. Plus Celcuity's first approval.
Its biggest China upfront yet, right before Friday. Plus injectable Leqembi gets cleared.
Operation TrialBlazer is the carrot. Friday's deadline is the stick. Both aimed at the same problem.
Wainua flunked Phase 3. Meanwhile the China deadline hits Friday and the deals keep landing.
Eight days to the July 17 deadline and the deals keep coming. Plus Krazati stumbles and GSK walks.
Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
